MS Speaks

Multiple Sclerosis => TREATMENTS => OCREVUS (ocrelizumab) => Topic started by: agate on April 08, 2019, 03:03:16 pm

Title: Fulminant hepatitis associated w/Echovirus 25 during Ocrevus treatment...
Post by: agate on April 08, 2019, 03:03:16 pm

I may be giving too much attention to rare, anecdotal instances of adverse effects of the MS disease-modifying drugs, but here is another one. This MS patient was taking Ocrevus but ended up getting a liver transplant--and stopping the Ocrevus.  This is from JAMA Neurology (April 8, 2019), "Fulminant hepatitis associated with Echovirus 25 during treatment with ocrelizumab for multiple sclerosis":


http://bit.ly/2WXuNQ6


This is from the discussion:

Quote

Because ocrelizumab is a novel, high-efficacy disease-modifying therapy for MS, it will probably be extensively used. However, it may impair clearance of enterovirus infections via B-cell depletion. Thus, in the case of compatible symptoms, tests should be conducted for enteroviruses. Given the bimodal clinical presentation (ie, the patient had a severe rebound of liver enzyme levels after initial improvement), patients receiving ocrelizumab with enteroviral infection need close follow-up.

Title: Re: Fulminant hepatitis associated w/Echovirus 25 during Ocrevus treatment...
Post by: ewizabeth on July 17, 2019, 06:54:25 am

I was required to get tested for all forms of hepatitis prior to starting Ocrevus so now I know why. I was completely negative on all of them.